Catheter ablation of atrial fibrillation in patients with diabetes mellitus: A systematic review and meta-analysis

Europace

Volumn 17, Issue 10, 2015, Pages 1518-1525

  Anselmino, Matteo ^a   Matta, Mario ^a   D'Ascenzo, Fabrizio ^a   Pappone, Carlo ^b   Santinelli, Vincenzo ^b   Bunch, T Jared ^c   Neumann, Thomas ^d   Schilling, Richard J ^e   Hunter, Ross J ^e   Noelker, Georg ^f   Fiala, Martin ^g   Frontera, Antonio ^h   Thomas, Glyn ^h   Katritsis, Demosthenes ⁱ   Jais, Pierre ^k   Weerasooriya, Rukshen ^j,k   Kalman, Jonathan M ^l   Gaita, Fiorenzo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MARIA CECILIA HOSPITAL   (Italy)

^c INTERMOUNTAIN MEDICAL CENTER   (United States)

^d Kerckhoff Heart and Thorax Center ^*  (Germany)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g Department of Cardiology Heart Centre Hospital Podlesi As   (Czech Republic)

^h UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

ⁱ Athens Euroclinic   (Greece)

^j HAUT LÉVÊQUE HOSPITAL   (France)

^k UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^l ROYAL MELBOURNE HOSPITAL   (Australia)

more..

Author keywords

Atrial fibrillation; Catheter ablation; Diabetes mellitus; Meta analysis; Rhythm control

Indexed keywords

ANTICOAGULANT AGENT; GLYCOSYLATED HEMOGLOBIN; ORAL ANTIDIABETIC AGENT; ANTIARRHYTHMIC AGENT;

ARTICLE; ATRIAL FIBRILLATION; BODY MASS; CATHETER ABLATION; DIABETES MELLITUS; FOLLOW UP; GLYCEMIC CONTROL; GROUPS BY AGE; HEART ATRIUM FLUTTER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM CARE; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PAROXYSMAL ATRIAL FIBRILLATION; PATIENT SAFETY; PERSISTENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA; SYSTEMATIC REVIEW; THROMBOEMBOLISM; ADVERSE EFFECTS; PROCEDURES; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DIABETES COMPLICATIONS; HUMANS; RECURRENCE; TREATMENT OUTCOME;

EID: 84948453618     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv214     Document Type: Article

References (39)

1. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011; 108:56-62.
2. Anselmino M, Gohlke H, Mellbin L, Rydén L. Cardiovascular prevention in patients with diabetes and prediabetes. Herz 2008;33:170-7.
3. Andersson C, Gislason GH, Weeke P, Hoffmann S, Hansen PR, Torp-Pedersen C et al. Diabetes is associated with impaired myocardial performance in patients without significant coronary artery disease. Cardiovasc Diabetol 2010;9:3.
4. Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, Seoane-Blanco A, Moure-González M, Varela-Román A et al. Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol 2012;157:397-402.
5. Saunders J, Mathewkutty S, Drazner MH, McGuire DK. Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms. Herz 2008;33:184-90.
6. Anselmino M, Ohrvik J, Rydén L, Euro Heart Survey Investigators. Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2010;31:3040-5.
7. Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol 2013;168:4744-9.
8. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al., ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
9. Anselmino M, D'Ascenzo F, Amoroso G, Ferraris F, Gaita F. History of transcatheter atrial fibrillation ablation. J Cardiovasc Med 2012;13:1-8.
10. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc 2013;2:e004549.
11. Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 2009;20:22-8.
12. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
14. Wilczynski NL, Haynes RB, for the Hedges Team. Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey. BMC Med 2004;2:23.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36(Suppl. 1):S67-74. doi: 10.2337/dc13-S067.
16. Tang RB, Dong JZ, Liu XP, Fang DP, Long de Y, Liu XH et al. Safety and efficacy of catheter ablation of atrial fibrillation in patients with diabetes mellitus-single center experience. J Interv Card Electrophysiol 2006;17:41-6.
17. Chao TF, Suenari K, Chang SL, Lin YJ, Lo LW, Hu YF et al.Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J Cardiol 2010;106:1615-20.
18. Gu J, Liu X, Wang X, Shi H, Tan H, Zhou L et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 2011;13:1256-61.
19. Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003;42:185-97.
20. Gaita F, Caponi D, Scaglione M, Montefusco A, Corleto A, Di Monte F et al. Longterm clinical results of 2 different ablation strategies in patients with paroxysmal and persistent atrial fibrillation. Circ Arrhythm Electrophysiol 2008;1:269-75.
21. Katritsis D, Wood MA, Giazitzoglou E, Shepard RK, Kourlaba G, Ellenbogen KA. Long-term follow-up after radiofrequency catheter ablation for atrial fibrillation. Europace 2008;10:419-24.
22. Pappone C, Vicedomini G, Augello G, Manguso F, Saviano M, Baldi M et al. Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study. Circ Arrhythm Electrophysiol 2011;4: 808-14.
23. Medi C, Sparks PB, Morton JB, Kistler PM, Halloran K, Rosso R et al. Pulmonary vein antral isolation for paroxysmal atrial fibrillation: results from long-term follow-up. J Cardiovasc Electrophysiol 2011;22:137-41.
24. Weerasooriya R, Khairy P, Litalien J, Macle L, Hocini M, Sacher F et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011;57:160-6.
25. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol 2011;22:839-45.
26. Hunter RJ, McCready J, Diab I, Page SP, Finlay M, Richmond L et al. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart 2012;98:48-53.
27. Neumann T, Wójcik M, Berkowitsch A, Erkapic D, Zaltsberg S, GreissH et al. Cryoballoon ablation of paroxysmal atrial fibrillation: 5-year outcome after single procedure and predictors of success. Europace 2013;15:1143-9.
28. Vogt J, Heintze J, Gutleben KJ, Muntean B, Horstkotte D, Nölker G. Long-term outcomes after cryoballoon pulmonary vein isolation: results from a prospective study in 605 patients. J Am Coll Cardiol 2013;61:1707-12.
29. Fiala M, Wichterle D, Bulková V, Sknouril L, Nevralová R, Toman O et al. A prospective evaluation of haemodynamics, functional status, and quality of life after radiofrequency catheter ablation of long-standing persistent atrial fibrillation. Europace 2014;16:15-25.
30. Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P et al., Atrial Fibrillation Ablation Pilot Study Investigators. The Atrial Fibrillation Ablation Pilot Study: an European Survey on Methodology and Results of Catheter Ablation for Atrial Fibrillation: conducted by the European Heart Rhythm Association. Eur Heart J 2014;35:1466-78.
31. Arbelo E, Brugada J, Hindricks G, Maggioni A, Tavazzi L, Vardas P et al. ESCEURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace 2012; 14:1094-103.
32. Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A et al., ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009;30:1128-35.
33. Soran H, Younis N, Currie P, Silas J, Jones IR, Gill G. Influence of diabetes on the maintenance of sinus rhythm after a successful direct current cardioversion in patients with atrial fibrillation. QJM 2008;101:181-7.
34. Ito I, Hayashi Y, Kawai Y, Iwasaki M, Takada K, Kamibayashi T et al. Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers. Anesth Analg 2006;103: 545-50.
35. D'Ascenzo F, Corleto A, Biondi-Zoccai G, Anselmino M, Ferraris F, di Biase L et al. Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: a meta-analysis. Int J Cardiol 2013;167:1984-9.
36. Anselmino M, Malmberg K, Mellbin L, Rydén L. Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting. Rev Endocr Metab Disord 2010;11:87-94.
37. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013;310:2050-60.
38. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX et al. Long-term effect of goal directed weight management in an atrial fibrillation cohort: a Long-term Follow-Up StudY (LEGACY Study). J Am Coll Cardiol 2015. doi: 10.1016/j.jacc.2015.03.002.
39. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 2014; 64:2222-31.